


In the Claims

1. (currently amended) A formulation, comprising: an excipient selected from the group consisting of cyclodextrins, micelle forming agents, and polymeric carriers; and a compound represented by A:



A

wherein

m is 0, 1, 2, 3 or 4;

y is 0;

R₁ represents aryl or heteroaryl;

R₂ represents H, alkyl, or cycloalkyl;

R₃ represents H, alkyl, aryl, heteroaryl, or CH₂OR₂, or CO₂R₂;

R₄ represents aryl;

R₅ represents independently for each occurrence H, alkyl, or cycloalkyl;

R₆ represents independently for each occurrence H, alkyl, or cycloalkyl;

any two geminal or vicinal instances of R₅ and R₆ may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations.

2. (original) The formulation of claim 1, wherein the excipient is a cyclodextrin.

3. (original) The formulation of claim 1, wherein m is 2 or 3.
4. (original) The formulation of claim 1, wherein m is 2.
5. (canceled)
6. (canceled)
7. (original) The formulation of claim 1, wherein R₁ represents aryl.
8. (original) The formulation of claim 1, wherein R₂ represents independently for each occurrence alkyl.
9. (currently amended) The formulation of claim 1, wherein R₃ represents H or alkyl.
10. (canceled)
11. (canceled)
12. (original) The formulation of claim 1, wherein R₄ represents aryl.
13. (original) The formulation of claim 1, wherein R₅ represents independently for each occurrence H, or alkyl.
14. (original) The formulation of claim 1, wherein R₅ represents independently for each occurrence H.
15. (original) The formulation of claim 1, wherein R₆ represents independently for each occurrence H, or alkyl.
16. (original) The formulation of claim 1, wherein R₆ represents independently for each occurrence H.
17. (canceled)
18. (previously presented) The formulation of claim 1, wherein m is 2 and R₁ represents aryl.
19. (canceled)
20. (previously presented) The formulation of claim 1, wherein m is 2; R₁ represents aryl; and R₂ represents independently for each occurrence alkyl.
21. (canceled)


22. (canceled)

23. (currently amended) The formulation of claim 1, wherein m is 2; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; ~~R₃ represents H;~~ and R₅ represents independently for each occurrence H.

24. (currently amended) The formulation of claim 1, wherein m is 2; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; ~~R₃ represents H;~~ R₅ represents independently for each occurrence H; and R₆ represents independently for each occurrence H.

25. (currently amended) The formulation of claim 1, wherein m is 2; R₁ represents phenyl; R₂ represents independently for each occurrence ethyl; ~~R₃ represents H;~~ R₄ represents phenyl; R₅ represents independently for each occurrence H; and R₆ represents independently for each occurrence H.

26. (currently amended) A method of treating pain, drug addiction, or tinnitus in a mammal, comprising the step of orally administering to a mammal in need thereof an effective amount of a formulation of claim 1 comprising an excipient selected from the group consisting of cyclodextrins, micelle forming agents, and polymeric carriers; and a compound represented by A:



A

wherein

m is 0, 1, 2, 3 or 4;

y is 0;

R₁ represents aryl or heteroaryl;

R₂ represents H, alkyl, or cycloalkyl;

R₃ represents H, alkyl, aryl, heteroaryl, CH₂OR₂, or CO₂R₂;

R₄ represents aryl;

R₅ represents independently for each occurrence H, alkyl, or cycloalkyl;

R₆ represents independently for each occurrence H, alkyl, or cycloalkyl;

any two geminal or vicinal instances of R₅ and R₆ may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations.

27. (original) The method of claim 26, wherein said mammal is a primate, equine, canine or feline.

28. (original) The method claim 26, wherein said mammal is a human.

29. (canceled)